Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that vorolanib in combination with checkpoint inhibitors
(pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for
hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment
resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.